随着过继细胞疗法的出现，嵌合抗原受体（CAR）-T细胞疗法在癌症治疗中获得了广泛的应用，并已证明对某些血液恶性肿瘤具有显着疗效。然而，由于CAR-T细胞疗法在治疗实体瘤方面的局限性，其他免疫细胞正在用CAR进行修饰以解决这个问题。巨噬细胞因其广泛的免疫功能而成为一种有前景的选择，其中包括抗原呈递、强大的肿瘤吞噬作用，以及特别活跃的向肿瘤微环境的运输。利用其独特的优势，CAR-巨噬细胞（CAR-M）作为一种新型免疫疗法有望提高实体瘤治疗的有效性，有可能克服与 CAR-T/NK 治疗相关的主要挑战。本综述概述了 CAR-M 的主要机制和 CAR-M 治疗的最新进展，同时还讨论了它们的进一步应用。© 2024。作者。

With the advent of adoptive cellular therapy, chimeric antigen receptor (CAR)-T cell therapy has gained widespread application in cancer treatment and has demonstrated significant efficacy against certain hematologic malignancies. However, due to the limitations of CAR-T cell therapy in treating solid tumors, other immune cells are being modified with CAR to address this issue. Macrophages have emerged as a promising option, owing to their extensive immune functions, which include antigen presentation, powerful tumor phagocytosis, and particularly active trafficking to the tumor microenvironment. Leveraging their unique advantages, CAR-macrophages (CAR-M) are expected to enhance the effectiveness of solid tumor treatments as a novel form of immunotherapy, potentially overcoming major challenges associated with CAR-T/NK therapy. This review outlines the primary mechanism underlying CAR-M and recent progressions in CAR-M therapy, while also discussing their further applications.© 2024. The Author(s).